Koers Synta Pharmaceuticals Corp. Nasdaq
Aandelen
US87162T2069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 73,33 mln. 68,46 mln. | Omzet 2025 * | 364 mln. 340 mln. | Marktkapitalisatie | 5,97 mld. 5,57 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -584 mln. -545 mln. | Nettowinst (verlies) 2025 * | -405 mln. -378 mln. | EV/omzet 2024 * | 72 x |
Nettoliquiditeiten 2024 * | 694 mln. 647 mln. | Nettoliquiditeiten 2025 * | 292 mln. 272 mln. | EV/omzet 2025 * | 15,6 x |
K/w-verhouding 2024 * |
-10,1
x | K/w-verhouding 2025 * |
-15,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 82,81% |
Recentste transcriptie over Synta Pharmaceuticals Corp.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 01-09-11 |
William Sibold
CEO | Chief Executive Officer | 57 | 08-09-23 |
Rebecca Taub
FOU | Founder | 71 | 01-07-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fred Craves
FOU | Founder | 78 | 01-09-11 |
Julian Baker
CHM | Chairman | 57 | 15-06-23 |
Ken Bate
BRD | Director/Board Member | 73 | 22-07-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+18,95% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,03% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |
- Beurs
- Aandelen
- Koers MDGL
- Koers